*See NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for AML, Version 2.2021, for complete recommendations. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Actionable mutations include   IDH1/2 and FLT3.
AML=acute myeloid leukemia; CI=confidence interval; PBO=placebo; HR=hazard ratio; IDH=isocitrate dehydrogenase; FLT=fms-like tyrosine kinase.

Capsules Icon

Learn about initiation & dosing management

Financial Support Icon

Access patient & financial support
 

Representative Icon

Contact a representative for 1:1 support

US-VENA-210053/April 2021